机构:[1]Department of General Practice, XuanWu Hospital of Capital Medical University, Beijing, China首都医科大学宣武医院普通外科[2]Department of Geriatrics, XuanWu Hospital of Capital Medical University, Beijing, China内科系统老年医学科首都医科大学宣武医院[3]Department of Neurology, XuanWu Hospital of Capital Medical University, Beijing, China神经科系统神经内科首都医科大学宣武医院[4]Department of General Surgery, XuanWu Hospital of Capital Medical University, Beijing, China外科系统普通外科首都医科大学宣武医院[5]Radiological Sciences, Division of Clinical Neuroscience, Queen’s Medical Centre, University of Nottingham, Nottingham, United Kingdom[6]National Clinical Research Center for Geriatric Disorders, Beijing, China[7]Center of Alzheimer’s Disease, Beijing Institute for Brain Disorders, Beijing, China
Background Since SCD (plus) was standardized, little is known about its demographic characteristics and its outcomes of neuropsychological assessments, including the SCD questionnaire 9 (SCD-Q9). Objective To characterize SCD (plus) by comparing the neuropsychological features among its subgroups and with normal controls (NC). Also, to explore its demographics and to understand the relation of the chief complaints and the scores of SCD-Q9. Methods Multistage stratified cluster random sampling was conducted to select participants. As a result, 84 NC and 517 SCD (plus) were included. SCD (plus) was further classified into several subgroups (SCD-C: concerned cognitive decline; SCD-F: complaints about SCD within the past five years; SCD-P: feeling performance being not as good as their peers; SCD+: presented> 3 of SCD (plus) features; SCD-: presented <= 3 of SCD (plus) features (see the diagnostic criteria for the details)) and between-group comparisons of neuropsychological scores were conducted. Point-biserial correlation and binary logistic regression analyses were performed to investigate the demographic characteristics of its subgroups. Finally, Spearman correlation was used to better understand the relation of SCD (plus) to SCD-Q9. Results (1) Scores of AVLT-LR (AVLT-LR: Auditory Verbal Learning Test-Long Delayed Recall) and MoCA-B (MoCA: Montreal Cognitive Assessment-Basic) were lower in the SCD-P group than those in the NC group, and the SCD+ group scored lower in the MoCA-B and CDT(CDT: Clock Drawing Test) than the SCD- group. (2) Females were more concerned than male participants. Individuals with lower education level felt that their cognitive performance were worse than their peers. Also, younger people might express concerns more than the more elderly. People who had complaints of SCD-P might be more likely to report SCD-C, but less likely to report SCD-F. (3) Positive correlations were found between the chief complaints of SCD (plus) and some items of SCD-Q9. Conclusions SCD (plus) may be related to demographic factors. Individuals with SCD (plus) already exhibited cognitive impairment, which can be detected by SCD-Q9.
基金:
National Key Research and Development Program of China [2018YFC1312000]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China [61633018]
第一作者机构:[1]Department of General Practice, XuanWu Hospital of Capital Medical University, Beijing, China[2]Department of Geriatrics, XuanWu Hospital of Capital Medical University, Beijing, China
共同第一作者:
通讯作者:
通讯机构:[*1]XuanWu Hospital of Capital Medical University, Beijing, China.[*2]Division of Clinical Neuroscience, Queen’s Medical Centre, University of Nottingham.
推荐引用方式(GB/T 7714):
Hao Lixiao,Sun Yu,Li Yun,et al.Demographic characteristics and neuropsychological assessments of subjective cognitive decline (SCD) (plus)[J].ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY.2020,7(6):1002-1012.doi:10.1002/acn3.51068.
APA:
Hao, Lixiao,Sun, Yu,Li, Yun,Wang, Jieyu,Wang, Zichen...&Han, Ying.(2020).Demographic characteristics and neuropsychological assessments of subjective cognitive decline (SCD) (plus).ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY,7,(6)
MLA:
Hao, Lixiao,et al."Demographic characteristics and neuropsychological assessments of subjective cognitive decline (SCD) (plus)".ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY 7..6(2020):1002-1012